Teología de la praxis educativa en la pedagogía salesiana : la educación es cuestión del corazón

La teología de la acción humana ejerce un proceso de reflexión y respuesta a los distintos problemas que trae la sociedad y el sujeto en su complejidad, abordándose como interlocutor válido de conocimiento y contribuyendo a la comprensión de la realidad, desde la óptica de la revelación y de la fe cristiana; estas realidades se correlacionan y se interpretan a la luz de la situación concreta del sujeto en relación con los principios del Evangelio, encontrando allí, en la Buena Nueva de Jesús, una fuente para la vida, una vida que se hace vida con los hechos y las palabras. Es decir, la teología de la praxis es la posibilidad de “acompañar la acción propia y ajena, bajo la óptica del plan salvífico de Dios, que integran el obrar y la vocación humana en cuanto actividad en el mundo.” La praxis educativa y el modelo pedagógico salesiano está permeado por el pretexto de la liberación, es decir, de la acción liberadora y salvífica de Dios a lo largo de la historia humana, como resultado de una dinámica y estructura de la acción de amor de Dios hacia el pueblo sufriente que espera el amor y la justicia práxica como responsabilidad y construcción de querer humanizar día a día. Por ello, la acción humana como praxis educativa y liberadora, se empeña en la construcción del Reino, desde la opción por el empobrecido, en la perspectiva de la pedagogía de Don Bosco y de la civilización del amor, para valorar en el acto pedagógico un nuevo lugar interpretativo para comprender y transformar el mundo y la acción.The theology of human action exercises a process of reflection and response to the different problems that society and the subject bring in their complexity, addressing themselves as a valid interlocutor of knowledge and contributing to the understanding of reality, from the perspective of revelation and Of the Christian faith; These realities are correlated and interpreted in the light of the concrete situation of the subject in relation to the principles of the Gospel, finding there, in the Good News of Jesus, a source for life, a life that becomes alive with facts and words. That is to say, the theology of praxis is the possibility of "accompanying one's own and others' actions, under the perspective of God's plan of salvation, which integrate action and the human vocation as an activity in the world."Magíster en TeologíaMaestrí

Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd